Mitochondrial Transfer May Open

How Could Mitochondria Affect Chronic Nerve Pain?

Neuropathic pain is different from ordinary short-term pain after an injury. It can persist after tissues heal because the nerves themselves become damaged or overactive, producing burning, tingling, electric-shock sensations or pain from light touch. The CDC has reported that chronic pain affects about one in five U.S. adults, and neuropathic pain is one of the harder forms to treat because it arises from altered nerve function rather than only from inflammation in surrounding tissue.

The Duke-led Nature study focuses on the dorsal root ganglia, clusters of sensory nerve cell bodies that relay touch, temperature and pain information to the spinal cord and brain. These neurons have long extensions reaching into the skin and limbs, which creates a major energy challenge. When mitochondrial supply and function decline, nerves may become vulnerable to degeneration, abnormal firing and pain amplification.

What Did The Duke Study Find In Damaged Nerves?

The research team studied mouse models, human dorsal root ganglion tissue and cell systems to examine how support cells called satellite glial cells interact with sensory neurons. They identified tunneling nanotube-like structures that appear to help move mitochondria from glial cells into neurons, with the protein MYO10 playing an important role in that transfer process.

In preclinical models of diabetic neuropathy and chemotherapy-induced nerve injury, boosting this mitochondrial exchange reduced pain behaviors, with Duke reporting reductions of about 40% to 50% within a day in some mouse experiments. Direct delivery of isolated healthy mitochondria to the dorsal root ganglia also eased pain in models, while mitochondria from people with diabetes did not show the same effect, suggesting that mitochondrial quality may matter as much as quantity.

Could This Become A New Neuropathy Treatment?

The findings are important because many current neuropathic pain treatments, including certain antidepressants, antiseizure medicines and topical therapies, mainly reduce pain signaling rather than repairing the underlying nerve injury. A strategy that restores energy support between glial cells and neurons could represent a different therapeutic approach, especially for diabetic neuropathy and chemotherapy-induced peripheral neuropathy.

Major questions remain before this can move into routine care. Researchers still need to determine how to deliver or stimulate healthy mitochondrial transfer safely, how long the effect can last, whether repeated treatment would be needed and whether the approach can work in people with long-standing neuropathy. For now, the study should be viewed as mechanistic and preclinical, not as a replacement for evidence-based pain care.